---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-23-000019"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T11:42:15.513542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q1 sales $1.46B (+9% YoY), adj EPS $0.62; raises FY guidance, CEO to retire

## Summary
- Q1 GAAP EPS $0.56; adjusted EPS $0.62 vs prior guidance implied range.
- TAVR sales $948M (+8% YoY, +11% cc); TMTT $42M; Surgical $248M; Critical Care $222M.
- Full-year sales guidance raised to high end of $5.6-6.0B; adj EPS guidance raised to $2.48-2.60.
- Repurchased ~$250M stock in Q1; free cash flow $253M.
- CEO Michael Mussallem retiring next month; Bernard Zovighian to succeed.

## SEC filing metadata
- accession: 0001099800-23-000019
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/0001099800-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/ew-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-23-000019
- JSON: https://secwatch.observer/filing/0001099800-23-000019.json
- Plain text: https://secwatch.observer/filing/0001099800-23-000019.txt

## Key facts
- Earnings Releases
  Edwards Lifesciences Corp reported the quarter ended March 31, 2023 results: revenue $1.46 billion, EPS $0.56. Guidance raised.
  - Period: the quarter ended March 31, 2023
  - Revenue: $1.46 billion
  - EPS: $0.56
  - Guidance: raised
  - Result: reported results
  source text: April 26, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook • Q1 sales grew 9 percent to $1.46 billion; constant currency 1 sales grew 13 percent • Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent • Q1 EPS of $0.56; adjusted 1 EPS of $0.62 • Repurchased
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000019/0001099800-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.